Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. (Q47887637)
Jump to navigation
Jump to search
scientific article published in May 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. |
scientific article published in May 2004 |
Statements
Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer (English)
Colby L Eaton
Jason M Wells
Freddie C Hamdy